In the randomized phase III RATIFY study (NCT00651261), the addition of midostaurin to chemotherapy significantly improved OS and event-free survival in adults with newly diagnosed AML and an FLT3 mutation compared with placebo (21). The gene discussed is FLT3; the disease is acute myeloid leukemia.